440 results on '"Neonatal Sepsis drug therapy"'
Search Results
2. Prevalence of carbapenem-resistant gram-negative bacteria among neonates suspected for sepsis in Africa: a systematic review and meta-analysis.
- Author
-
Sisay A, Asmare Z, Kumie G, Gashaw Y, Getachew E, Ashagre A, Nigatie M, Ayana S, Misganaw T, Dejazmach Z, Abebe W, Gedfie S, Tadesse S, Gashaw M, Jemal A, Kassahun W, Kidie AA, Abate BB, Mulugeta C, Alamrew A, and Reta MA
- Subjects
- Humans, Infant, Newborn, Africa epidemiology, Drug Resistance, Bacterial, Microbial Sensitivity Tests, Prevalence, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Carbapenems pharmacology, Carbapenems therapeutic use, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections epidemiology, Gram-Negative Bacterial Infections microbiology, Gram-Negative Bacterial Infections drug therapy, Neonatal Sepsis epidemiology, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy
- Abstract
Background: The emergence and rapid spread of gram-negative bacteria resistant to carbapenems among newborns is concerning on a global scale. Nonetheless, the pooled estimate of gram-negative bacteria resistant to carbapenem that cause neonatal sepsis in developing nations remains unknown. Thus, this study aimed to determine the combined prevalence of gram-negative bacteria resistant to carbapenem in African newborns who were suspected of having sepsis., Methods: All studies published from January 1, 2010, up to December 30, 2023, from PubMed, Science Direct, Scopus electronic databases, and the Google Scholar search engine were researched. Isolates tested for carbapenem from neonates with sepsis, English language papers conducted in Africa, and cross-sectional and cohort studies papers were included. Using PRISMA guidelines, we systematically reviewed and meta-analyzed studies that assessed the prevalence of carbapenem-resistant gram-negative bacteria. The "Joanna Briggs Institute" was used critically to evaluate the quality of the included studies. The data analysis was carried out using STATA™ version 17. Heterogeneity across the studies was evaluated using Q and I
2 tests. The subgroup analysis was done and, funnel plot and Egger's regression test were used to detect publication bias. A sensitivity analysis was conducted., Results: All 36 studies were included in the meta-analysis and systematic review. The pooled prevalence of carbapenem resistance in Africa was 30.34% (95% CI 22.03-38.64%). The pooled estimate of gram-negative bacteria resistant to imipenem, and meropenem was 35.57% (95% CI 0.67-70.54%) and 34.35% (95% CI 20.04% - 48.67%), respectively. A. baumannii and Pseudomonas spp. had pooled prevalence of 45.9% (95% CI 33.1-58.7%) and 43.0% (95% CI 23.0-62.4%), respectively. Similarly, Pseudomonas spp. and A. baumannii also exhibited strong meropenem resistance, with a pooled prevalence of 29.2% (95% CI 4.8-53.5%) and 36.7% (95% CI 20.1-53.3%), respectively. E. coli and K. pneumoniae were the two most common isolates., Conclusion: There should be urgent antimicrobial stewardship practices, strengthened surveillance systems and effective treatment for neonates with sepsis. There was remarkable variation in resistance across the continent., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
3. Clinical Course and Outcomes of Infants with Streptococcus bovis/Streptococcus Gallolyticus subspecies pasteurianus Infection: A Systematic Review and Meta-analysis.
- Author
-
Jaya-Bodestyne SL, Tan YY, Sultan R, Yeo KT, and Kong JY
- Subjects
- Humans, Infant, Newborn, Infant, Female, Streptococcus gallolyticus subspecies gallolyticus, Male, Treatment Outcome, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Neonatal Sepsis mortality, Streptococcal Infections microbiology, Streptococcal Infections drug therapy, Streptococcal Infections mortality, Streptococcus bovis, Anti-Bacterial Agents therapeutic use
- Abstract
Background: Streptococcus gallolyticus subspecies pasteurianus (SGP), a subtype of Streptococcus bovis , is an uncommon but important cause of neonatal sepsis. Although uncommon, SGP infections during infancy have been associated with an increased risk of morbidity and mortality., Methods: This is a systematic review and meta-analysis of available literature on the clinical course and outcomes of infants with SGP infection. Studies were identified using the following MeSH keywords: " Streptococcus gallolyticus ," " Streptococcus bovis ," "newborn" and "infant." Data including perinatal factors, clinical presentation, investigations, treatment and outcomes were extracted and analyzed., Results: A total of 46 articles were identified (116 cases: 60 S. bovis , 56 SGP). The cases were predominantly term (52%), male (57%) and born via vaginal delivery (67%). The most common symptom was fever [67% (95% confidence interval (CI): 43%-84%)], lethargy [66% (95% CI: 32%-89%)], tachypnea [59% (95% CI: 27%-85%)] and irritability [59% (95% CI: 34%-79%)]. Infants with early-onset infections (<3 days of life) were more likely to have respiratory symptoms and bacteremia (73%), whereas late-onset infections presented predominantly with gastrointestinal symptoms. Four mortalities were reported which occurred before antibiotic administration. Isolated bacteria were mostly penicillin-susceptible [95% (95% CI: 78-99%)] and cases treated with penicillin derivative had good recovery., Conclusions: SGP is an important cause of neonatal sepsis and meningitis. Penicillin derivative is an effective treatment for SGP, and outcomes appear to be favorable., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Changing Landscape of Antimicrobial Resistance in Neonatal Sepsis: An in silico Analyses of Multidrug Resistance in Klebsiella pneumoniae.
- Author
-
Vijayakumar S, Kumar H, Basu S, Chandy S, Anbarasu A, Manoharan A, and Ramaiah S
- Subjects
- Humans, Infant, Newborn, Computer Simulation, beta-Lactams pharmacology, Fluoroquinolones pharmacology, Fluoroquinolones therapeutic use, beta-Lactamases genetics, beta-Lactamases metabolism, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae genetics, Neonatal Sepsis drug therapy, Neonatal Sepsis microbiology, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Klebsiella Infections drug therapy, Klebsiella Infections microbiology, Drug Resistance, Multiple, Bacterial genetics, Microbial Sensitivity Tests, Molecular Docking Simulation
- Abstract
Background: Neonatal sepsis poses a critical healthcare concern, as multidrug-resistant Klebsiella pneumoniae ( K. pneumoniae ) infections are on the rise. Understanding the antimicrobial susceptibility patterns and underlying resistance mechanism is crucial for effective treatment., Objectives: This study aimed to comprehensively investigate the antimicrobial susceptibility patterns of K. pneumoniae strains responsible for neonatal sepsis using in silico tools. We sought to identify trends and explore reasons for varying resistance levels, particularly for β-lactams and fluoroquinolone., Methods: K. pneumoniae isolated from neonates at Kanchi Kamakoti CHILDS Trust Hospital (2017-2020) were analyzed for antimicrobial resistance. Elevated resistance to β-lactam and fluoroquinolone antibiotics was further investigated through molecular docking and interaction analysis. β-lactam affinity with penicillin-binding proteins and β-lactamases was examined. Mutations in ParC and GyrA responsible for quinolone resistance were introduced to investigate ciprofloxacin interactions., Results: Of 111 K. pneumoniae blood sepsis isolates in neonates, high resistance was detected to β-lactams such as cefixime (85.91%, n = 71), ceftriaxone (84.9%, n = 106), cefotaxime (84.9%, n = 82) and fluoroquinolone (ciprofloxacin- 79.44%, n = 107). Molecular docking revealed low β-lactam binding toward penicillin-binding proteins and higher affinities for β-lactamases, attributing to the reduced β-lactam efficiency. Additionally, ciprofloxacin showed decreased affinity toward mutant ParC and GyrA in comparison to their corresponding wild-type proteins., Conclusion: Our study elucidates altered resistance profiles in neonatal sepsis caused by K. pneumoniae , highlighting mechanisms of β-lactam and fluoroquinolone resistance. It underscores the urgent need for the development of sustainable therapeutic alternatives to address the rising antimicrobial resistance in neonatal sepsis., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Predictors of gentamicin therapy failure in neonates with sepsis.
- Author
-
Singu BS, Pieper CH, Verbeeck RK, and Ette EI
- Subjects
- Humans, Infant, Newborn, Cross-Sectional Studies, Prospective Studies, Female, Male, Neonatal Sepsis drug therapy, C-Reactive Protein analysis, Sepsis drug therapy, Sepsis mortality, Birth Weight, Ampicillin therapeutic use, Ampicillin administration & dosage, Gentamicins therapeutic use, Gentamicins administration & dosage, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Treatment Failure, Intensive Care Units, Neonatal statistics & numerical data
- Abstract
Sepsis is a common disease with high morbidity and mortality among newborns in intensive care units world-wide. Gram-negative bacillary bacteria are the major source of infection in neonates. Gentamicin is the most widely used aminoglycoside antibiotic in empiric therapy against early-onset sepsis. However, therapy failure may result due to various factors. The purpose of this study was to identify predictors of gentamicin therapy failure in neonates with sepsis. This was a prospective cross-sectional study at the Neonatal Intensive Care Unit at Windhoek Central Hospital over a period of 5 months in 2019. Neonates received intravenous gentamicin 5 mg/kg/24 h in combination with either benzylpenicillin 100 000 IU/kg/12 h or ampicillin 50 mg/kg/8 h. Logistic regression modeling was performed to determine the predictors of treatment outcomes. 36% of the 50 neonates were classified as having gentamicin treatment failure. Increasing treatment duration by 1 day resulted in odds of treatment failure increasing from 1.0 to 2.41. Similarly, one unit increase in CRP increases odds of gentamicin treatment failure by 49%. The 1 kg increase in birthweight reduces the log odds of treatment failure by 6.848, resulting in 99.9% decrease in the odds of treatment failure. One unit increase in WBC reduces odds of gentamicin treatment failure by 27%. Estimates of significant predictors of treatment failure were precise, yielding odds ratios that were within 95% confidence interval. This study identified the following as predictors of gentamicin therapy failure in neonates: prolonged duration of treatment, elevated C-reactive protein, low birthweight, and low white blood cell count., (© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Late-onset sepsis in newborns caused by Bacillus Cereus: a case report and literature review.
- Author
-
Zhang W, Ma C, Hu L, Wang L, and Xu F
- Subjects
- Humans, Infant, Newborn, Anti-Bacterial Agents therapeutic use, Bacillus cereus isolation & purification, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections microbiology, Gram-Positive Bacterial Infections diagnosis, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Neonatal Sepsis diagnosis
- Abstract
Bacillus cereus is a bacterium capable of causing late-onset neonatal sepsis. By analyzing 11 cases, this study investigates the diagnosis, treatment, and prognosis of Bacillus cereus infections, aiming to provide insights into clinical diagnosis and therapy. The study scrutinized 11 instances of late-onset neonatal sepsis, including two fatalities attributable to Bacillus cereus, one accompanied by cerebral hemorrhage. An examination and analysis of these cases' symptoms, signs, laboratory tests, and treatment processes, along with a review of related literature from 2010 to 2020, revealed a high mortality rate of 41.38% in non-gastrointestinal infections caused by Bacillus cereus. Our findings underscore the critical importance of rapid diagnosis and effective antimicrobial therapy in reducing mortality rates. Once the source of infection is identified, implementing effective infection control measures is essential., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. Shorter versus longer duration antibiotic regimens for treatment of culture-positive neonatal sepsis.
- Author
-
Legge AA, Middleton JL, Fiander M, Cracknell J, Osborn DA, and Gordon A
- Subjects
- Humans, Infant, Newborn, Drug Administration Schedule, Randomized Controlled Trials as Topic, Time Factors, Systematic Reviews as Topic, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis drug therapy
- Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the safety and effectiveness of shorter versus longer duration antibiotic regimens for the treatment of culture-positive neonatal sepsis with or without meningitis., (Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
8. Role of central endpoint adjudication and challenges in trials on neonatal sepsis-a case of ProSPoNS trial.
- Author
-
Sinha AP, Raja D, Mahajan KS, Sharma P, Gupta SS, Poluru R, Kawade AS, Dayma G, Sazawal S, Bavdekar A, Parida S, Nangia S, Raut AV, Bethou A, Devi P, Gorpade M, Fatima T, Nayak R, Kapil A, Azam M, Khan PA, Pandey RM, and Arora NK
- Subjects
- Humans, Infant, Newborn, Endpoint Determination standards, India, Infant Mortality, Probiotics therapeutic use, Probiotics adverse effects, Randomized Controlled Trials as Topic, Research Design, Sample Size, Treatment Outcome, Clinical Trial Protocols as Topic, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy
- Abstract
Despite progress in reducing the infant mortality in India, the neonatal mortality decline has been slower, necessitating concerted efforts to achieve Sustainable Development Goal-3. A promising strategy aiming to prevent neonatal sepsis in high-risk, vulnerable, low birth weight neonates through an innovative intervention includes probiotic supplementation. This article communicates the decision by the ProSPoNS trial investigators to establish a Central Endpoint Adjudication Committee (CEAC) as an addendum to the protocol published in Trials in 2021 for the purpose of clarifying the primary outcome. In the published protocol, the study hypothesis and primary objective are based on "sepsis," the primary outcome has been specified as sepsis/PSBI, whereas the sample size estimation was performed based on the "physician diagnosed sepsis." To align all the three above, the investigators meeting, held on 17th-18th August 2023, at MGIMS Sevagram, Wardha, deliberated and unanimously agreed that "physician diagnosed sepsis" is the primary study outcome which includes sepsis/PSBI. The CEAC, chaired by an external subject expert and members including trial statistician, a microbiologist, and all site principal investigators will employ four criteria to determine "physician diagnosed sepsis": (1) blood culture status, (2) sepsis screen status, (3) PSBI/non-PSBI signs and symptoms, and (4) the clinical course for each sickness event. Importantly, this clarification maintains consistency with the approved study protocol (Protocol No. 5/7/915/2012 version 3.1 dated 14 Feb 2020), emphasizing the commitment to methodological transparency and adherence to predefined standards. The decision to utilize the guidance of a CEAC is recommended as the gold standard in multicentric complex clinical trials to achieve consistency and accuracy in assessment of outcomes.Trial registrationClinical Trial Registry of India (CTRI) CTRI/2019/05/019197. Registered on 16 May 2019., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. Analysis of Differences in Neonatal Sepsis Caused by Streptococcus Agalactiae and Escherichia Coli.
- Author
-
Que C, Chen H, Qiu H, and Zhong H
- Subjects
- Humans, Infant, Newborn, Female, Retrospective Studies, Male, Microbial Sensitivity Tests, Drug Resistance, Bacterial, Streptococcus agalactiae drug effects, Streptococcus agalactiae isolation & purification, Neonatal Sepsis microbiology, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Escherichia coli drug effects, Escherichia coli isolation & purification, Streptococcal Infections microbiology, Streptococcal Infections epidemiology, Streptococcal Infections drug therapy, Streptococcal Infections diagnosis, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Escherichia coli Infections microbiology, Escherichia coli Infections epidemiology, Escherichia coli Infections diagnosis, Escherichia coli Infections drug therapy
- Abstract
Background: Streptococcus agalactiae (GBS) and Escherichia coli (E. coli) are the main pathogenic bacteria in neonatal sepsis. Therefore, the clinical characteristics, nonspecific indicators, and drug susceptibilities of these two bacteria were studied., Methods: In total, 81 and 80 children with sepsis caused by GBS and E. coli infection, respectively, admitted to the neonatal department of our hospital between May 2012 and July 2023, were selected, and the clinical characteris-tics of the two groups were analyzed. Nonspecific indicators and drug sensitivity test results were analyzed retrospectively., Results: Birth weight, tachypnea, groan, tachycardia or bradycardia, and the incidence of complications, such as pneumonia, respiratory failure, and purulent meningitis, were higher in the GBS group than in the E. coli group. The children were born prematurely, and the mother had a premature rupture of membranes. The incidence of jaundice, abdominal distension, atypical clinical manifestations, and complications of necrotizing enterocolitis was lower than of the E. coli group, and the differences were statistically significant (p < 0.05). The WBC, NE#, NE#/LY#, hs-CRP, and PCT of the GBS group were higher than those of the E. coli group, whereas the MPV, D-D, and FDP levels were lower than those in the E. coli group. The differences were all statistically significant (p < 0.05). The 81-bead GBS had high resistance rates against tetracycline (95%), erythromycin (48.8%), and clindamycin (40%), and no strains resistant to vancomycin, linezolid, penicillin, or ampicillin appeared, whereas 80 strains of E. coli were more resistant to penicillin and third-generation cephalosporins, with the higher resistance rates to ampicillin (68.30%), trimethoprim/sulfamethoxazole (53.6%), and ciprofloxacin (42.90%). Resistance rates to carbapenems and aminoglycosides were extremely low., Conclusions: Both GBS and E. coli neonatal sepsis have specific clinical characteristics, especially in terms of clinical manifestations, complications, non-specific indicators, and drug resistance. Early identification is important for clinical diagnosis and treatment.
- Published
- 2024
- Full Text
- View/download PDF
10. Optimal use of β-lactams in neonates: machine learning-based clinical decision support system.
- Author
-
Tang BH, Yao BF, Zhang W, Zhang XF, Fu SM, Hao GX, Zhou Y, Sun DQ, Liu G, van den Anker J, Wu YE, Zheng Y, and Zhao W
- Subjects
- Humans, Infant, Newborn, Neonatal Sepsis drug therapy, Neonatal Sepsis diagnosis, Microbial Sensitivity Tests, Algorithms, beta-Lactams administration & dosage, beta-Lactams therapeutic use, Machine Learning, Decision Support Systems, Clinical, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage
- Abstract
Background: Accurate prediction of the optimal dose for β-lactam antibiotics in neonatal sepsis is challenging. We aimed to evaluate whether a reliable clinical decision support system (CDSS) based on machine learning (ML) can assist clinicians in making optimal dose selections., Methods: Five β-lactam antibiotics (amoxicillin, ceftazidime, cefotaxime, meropenem and latamoxef), commonly used to treat neonatal sepsis, were selected. The CDSS was constructed by incorporating the drug, patient, dosage, pharmacodynamic, and microbiological factors. The CatBoost ML algorithm was used to build the CDSS. Real-world studies were used to evaluate the CDSS performance. Virtual trials were used to compare the CDSS-optimized doses with guideline-recommended doses., Findings: For a specific drug, by entering the patient characteristics and pharmacodynamic (PD) target (50%/70%/100% fraction of time that the free drug concentration is above the minimal inhibitory concentration [fT > MIC]), the CDSS can determine whether the planned dosing regimen will achieve the PD target and suggest an optimal dose. The prediction accuracy of all five drugs was >80.0% in the real-world validation. Compared with the PopPK model, the overall accuracy, precision, recall, and F1-Score improved by 10.7%, 22.1%, 64.2%, and 43.1%, respectively. Using the CDSS-optimized doses, the average probability of target concentration attainment increased by 58.2% compared to the guideline-recommended doses., Interpretation: An ML-based CDSS was successfully constructed to assist clinicians in selecting optimal β-lactam antibiotic doses., Funding: This work was supported by the National Natural Science Foundation of China; Distinguished Young and Middle-aged Scholar of Shandong University; National Key Research and Development Program of China., Competing Interests: Declaration of interests All authors declare that they have no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Antibiotic Stewardship in Chorioamnionitis Exposed Neonates, A Quality Improvement Project.
- Author
-
Grev JE, Van Tol M, Welker B, Schumacher B, Mulder L, Dykstra A, and Richards L
- Subjects
- Humans, Infant, Newborn, Female, Pregnancy, Risk Assessment, Length of Stay statistics & numerical data, Quality Improvement, Antimicrobial Stewardship, Chorioamnionitis drug therapy, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis drug therapy
- Abstract
Background: Rates of neonatal early onset sepsis (EOS) in term infants have recently decreased. The 2018 AAP guidelines for the management of infants at risk for early onset sepsis allows for using a multivariate risk assessment to determine need for empiric antibiotics in infants 35 weeks or greater, including those exposed to chorioamnionitis., Methods: A quality improvement (QI) project was undertaken to implement use of EOS calculator in chorioamnionitis exposed infants with an aim to safely decrease antibiotic exposure. Multiple Plan-Do-Study-Act (PDSA) cycles occurred to implement the change. Data regarding antibiotics, labs, length of stay and safety metrics were collected., Results: Implementing the EOS calculator's use in chorioamnionitis exposed neonates decreased antibiotic exposure from 100% to 75%, and decreased average duration of antibiotics from 68 to 40 hours. Implementation decreased prolonged courses of antibiotics, lumbar punctures, length of stay and laboratory tests. No cases of early culture confirmed EOS were missed, and none occurred in this well appearing population., Conclusions: Quality improvement initiatives to implement evidence-based tools can safely and appropriately decrease antibiotic exposure in neonates., (Copyright© South Dakota State Medical Association.)
- Published
- 2024
12. The Validity of Positive Coagulase-Negative Staphylococcus Cultures for the Diagnosis of Sepsis in the Neonatal Unit.
- Author
-
Benenson S, Cohen MJ, Greenglick N, Schwartz C, Eventov-Friedman S, and Ergaz Z
- Subjects
- Humans, Infant, Newborn, Female, Male, Israel, Vancomycin therapeutic use, Neonatal Sepsis diagnosis, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Intensive Care Units, Neonatal, Staphylococcus isolation & purification, Staphylococcus enzymology, Staphylococcal Infections diagnosis, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology, Coagulase metabolism, Blood Culture, Anti-Bacterial Agents therapeutic use, Bacteremia diagnosis, Bacteremia microbiology, Bacteremia drug therapy
- Abstract
Objective: Coagulase-negative Staphylococcus (CoNS) is the most frequent pathogen causing late-onset sepsis (LOS) in neonatal intensive care units (NICUs). Technical difficulties hinder blood culture (BC) collection and obtaining only one culture before initiating antibiotic therapy is a common practice. We sought to assess specific clinical information and CoNS cultures for the diagnosis of true bacteremia in the NICU., Study Design: This historical cohort study was conducted in NICUs at the Hadassah-Hebrew University Medical Center of Jerusalem in Israel. Clinical and laboratory data in every CoNS bacteremia were collected and compared between bacteremia groups as follows: true positive, two positive BCs; contaminant, one positive BC out of two; undefined, one BC obtained and found positive., Results: For 3.5 years, CoNS was isolated in 139 episodes. True positive was identified in 44 of 139 (31.7%), contaminant in 42 of 139 (30.2%), and the event was undefined in 53 of 139 (38.1%). Vancomycin treatment was more frequent in the true positive and undefined groups than the contaminant group (100, 90.6, and 73.8% respectively, p = 0.001); treatment was also prolonged in these two groups ( p < 0.001). No clinical variables were associated with true bacteremia on multivariable analysis., Conclusion: Diagnosis should definitely be based on at least two positive BCs, despite objective difficulties in obtaining BCs in neonates., Key Points: · CoNS is a frequent pathogen causing LOS in neonates.. · Due to technical difficulties, often only one culture is collected prior to antibiotic therapy.. · No clinical/laboratory variables were associated with the diagnosis of true CoNS bacteremia.., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. 28 NICUs participating in a quality improvement collaborative targeting early-onset sepsis antibiotic use.
- Author
-
Payton KSE, Bennett MV, Schulman J, Benitz WE, Stellwagen L, Darmstadt GL, Quinn J, Kristensen-Cabrera AI, Breault CC, Bolaris M, Lefrak L, Merrill J, and Sharek PJ
- Subjects
- Humans, Infant, Newborn, Cross Infection drug therapy, Cross Infection prevention & control, Sepsis drug therapy, Female, Intensive Care Units, Neonatal, Quality Improvement, Antimicrobial Stewardship, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis drug therapy
- Abstract
Objective: There is widespread overuse of antibiotics in neonatal intensive care units (NICUs). The objective of this study was to safely reduce antibiotic use in participating NICUs by targeting early-onset sepsis (EOS) management., Study Design: Twenty-eight NICUs participated in this statewide multicenter antibiotic stewardship quality improvement collaborative. The primary aim was to reduce the total monthly mean antibiotic utilization rate (AUR) by 25% in participant NICUs., Result: Aggregate AUR was reduced by 15.3% (p < 0.001). There was a wide range in improvement among participant NICUs. There were no increases in EOS rates or nosocomial infection rates related to the intervention., Conclusion: Participation in this multicenter NICU antibiotic stewardship collaborative targeting EOS was associated with an aggregate reduction in antibiotic use. This study informs efforts aimed at sustaining improvements in NICU AURs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Machine Learning: A Potential Therapeutic Tool to Facilitate Neonatal Therapeutic Decision Making.
- Author
-
Tang BH, Li QY, Liu HX, Zheng Y, Wu YE, van den Anker J, Hao GX, and Zhao W
- Subjects
- Humans, Infant, Newborn, Clinical Decision-Making, Neonatal Sepsis drug therapy, Neonatal Sepsis diagnosis, Machine Learning, Anti-Bacterial Agents therapeutic use, Bacterial Infections drug therapy, Bacterial Infections diagnosis
- Abstract
Bacterial infection is one of the major causes of neonatal morbidity and mortality worldwide. Finding rapid and reliable methods for early recognition and diagnosis of bacterial infections and early individualization of antibacterial drug administration are essential to eradicate these infections and prevent serious complications. However, this is often difficult to perform due to non-specific clinical presentations, low accuracy of current diagnostic methods, and limited knowledge of neonatal pharmacokinetics. Although neonatal medicine has been relatively late to embrace the benefits of machine learning (ML), there have been some initial applications of ML for the early prediction of neonatal sepsis and individualization of antibiotics. This article provides a brief introduction to ML and discusses the current state of the art in diagnosing and treating neonatal bacterial infections, gaps, potential uses of ML, and future directions to address the limitations of current studies. Neonatal bacterial infections involve a combination of physiologic development, disease expression, and treatment response outcomes. To address this complex relationship, future models could consider appropriate ML algorithms to capture time series features while integrating influences from the host, microbes, and drugs to optimize antimicrobial drug use in neonates. All models require prospective clinical trials to validate their clinical utility before clinical use., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
15. The Novel MFG-E8-derived Oligopeptide, MOP3, Improves Outcomes in a Preclinical Murine Model of Neonatal Sepsis.
- Author
-
Nofi CP, Prince JM, Aziz M, and Wang P
- Subjects
- Animals, Mice, Animals, Newborn, Disease Models, Animal, Lung pathology, Lung metabolism, Mice, Inbred C57BL, Oligopeptides therapeutic use, RNA-Binding Proteins metabolism, Antigens, Surface therapeutic use, Milk Proteins therapeutic use, Neonatal Sepsis drug therapy
- Abstract
Introduction: Neonatal sepsis is a devastating inflammatory condition that remains a leading cause of morbidity and mortality. Milk fat globule-EGF-factor VIII (MFG-E8) is a glycoprotein that reduces inflammation, whereas extracellular cold-inducible RNA binding protein (eCIRP) worsens inflammation. This study aimed to determine the therapeutic potential of a novel MFG-E8-derived oligopeptide 3 (MOP3) designed to clear eCIRP and protect against inflammation, organ injury, and mortality in neonatal sepsis., Methods: C57BL6 mouse pups were injected intraperitoneally with cecal slurry (CS) and treated with MOP3 (20 μg/g) or vehicle. 10 h after injection, blood, lungs, and intestines were collected for analyses, and in a 7-day experiment, pups were monitored for differences in mortality., Results: MOP3 treatment protected septic pups from inflammation by reducing eCIRP, IL-6, TNFα, and LDH. MOP3 reduced lung and intestinal inflammation and injury as assessed by reductions in tissue mRNA levels of inflammatory markers, histopathologic injury, and apoptosis in lung and intestines. MOP3 also significantly improved 7-day overall survival for CS-septic mouse pups compared to vehicle (75% vs. 46%, respectively)., Conclusion: Deriving from MFG-E8 and designed to clear eCIRP, MOP3 protects against sepsis-induced inflammation, organ injury, and mortality in a preclinical model of neonatal sepsis, implicating it as an exciting potential new therapeutic., Level of Evidence: Level 1., Competing Interests: Conflicts of interest The authors (CN, MA, and PW) are inventors of the pending PCT application on “A chimeric molecule to treat septic patients”; EFS ID: 47240580; Application No.: 63433789. Other authors report no financial conflicts of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Neonatal Sepsis Due to Multidrug-resistant Bacteria at a Tertiary Teaching Hospital in Ethiopia.
- Author
-
Gashaw M, Ali S, Berhane M, Tesfaw G, Eshetu B, Workneh N, Seeholzer T, Froeschl G, Kroidl A, Wieser A, and Gudina EK
- Subjects
- Humans, Infant, Newborn, Ethiopia epidemiology, Male, Female, Longitudinal Studies, beta-Lactamases, Bacteria drug effects, Bacteria isolation & purification, Bacteria classification, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Tertiary Care Centers statistics & numerical data, Microbial Sensitivity Tests, Hospitals, Teaching statistics & numerical data
- Abstract
Background: The burden of multidrug-resistant bacterial infections in low-income countries is alarming. This study aimed to identify the bacterial etiologies and antibiotic resistance patterns among neonates in Jimma, Ethiopia., Methods: An observational longitudinal study was conducted among 238 presumptive neonatal sepsis cases tested with blood and/or cerebrospinal fluid culture. The bacterial etiologies were confirmed using matrix-assisted laser desorption ionization-time of flight mass spectrometry. The antibiotic resistance patterns were determined using the automated disc diffusion method (Bio-Rad) and the results were interpreted based on the European Committee on Antimicrobial Susceptibility Testing 2021 breakpoints. Extended-spectrum β-lactamases were detected using a double disc synergy test and confirmed by Mast discs (Mast Diagnostica GmbH)., Results: A total of 152 pathogens were identified. Of these, Staphylococcus aureus (18.4%) was the predominant isolate followed by Klebsiella pneumoniae (15.1%) and Escherichia coli (10.5%). All the isolates exhibited a high rate of resistance to first- and second-line antibiotics ranging from 73.3% for gentamicin to 93.3% for ampicillin. Furthermore, 74.4% of the Gram-negative isolates were extended-spectrum β-lactamase producers and 57.1% of S. aureus strains were methicillin resistant. The case fatality rate was 10.1% and 66.7% of the deaths were attributable to infections by multidrug-resistant pathogens., Conclusions: The study revealed a high rate of infections with multidrug-resistant pathogens. This poses a significant challenge to the current global and national target to reduce neonatal mortality rates. To address these challenges, it is important to employ robust infection prevention practices and continuous antibiotic resistance testing to allow targeted therapy., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
17. Relevance and antimicrobial resistance profile of Klebsiella pneumoniae in neonatal sepsis.
- Author
-
Ma H, Xu J, Zhang Y, Zhang R, and Wu J
- Subjects
- Infant, Humans, Infant, Newborn, Anti-Bacterial Agents therapeutic use, Klebsiella pneumoniae genetics, Drug Resistance, Bacterial, China, Microbial Sensitivity Tests, beta-Lactamases genetics, Neonatal Sepsis drug therapy, Sepsis microbiology, Klebsiella Infections drug therapy, Klebsiella Infections epidemiology, Klebsiella Infections microbiology
- Abstract
Background: Newborns are particularly susceptible to infection in hospitals, with neonatal sepsis being the most common infection symptom and the third leading cause of neonatal death. Klebsiella pneumoniae is a gram-negative bacterium of Enterobacteriaceae, which is a common pathogen of neonatal septicemia. In this study, we will analyze and evaluate the current status, clinical characteristics, and drug resistance of Klebsiella pneumoniae sepsis infection in Neonatal Intensive Care Unit (NICU), with the aim of providing effective basis for timely and accurate clinical diagnosis and treatment in clinical practice., Methods: Statistical analysis was performed on 75 cases of Enterobacteriaceae septicemia in infants admitted to NICU in a special obstetrics and gynecology hospital in Shanghai from January 2020 to June 2022. Based on bacterial identification, isolates were divided into the Klebsiella pneumoniae (KP) group ( n = 49) and the non-KP Enterobacteriaceae group ( n = 26). The infection, clinical characteristics, and bacterial resistance of the two groups of infected patients were compared., Results: Comparing the clinical characteristics of the two groups, the results showed that most of the subjects in the KP and non-KP groups were premature infants, accounting for 100% and 92.3% of subjects, respectively; late onset was the main disease in both groups, accounting for 93.9% and 80.8% of subjects, respectively. All patients received Peripherally Inserted Central Catheter(PICC). The levels of pro calcitonin and CRP (C-reactive protein) were significantly higher in the KP group compared with those in the non-KP group ( p < .05). At the same time, the incidence of thrombocytopenia in the KP group was significantly higher than that in the non-KP group ( p < .05). The proportion of antimicrobial drug exposure in the KP group is higher than that in the non-KP group. The drug resistance of the KP group to ceftazidime, ceftriaxone, cefepime, ampicillin/sulbactam, aztreonam, ciprofloxacin and compound sulfamethoxazole was significantly higher than that of the non-KP group, whereas the drug resistance rate to cefotetan, gentamycin and to bramycin was significantly lower than that of the non-KP group, Statistically significant differences ( p < .05). 38 cases of Klebsiella pneumoniae producing ESBLs were tested for related resistance genes. The results showed that the main resistance types were SHV and TEM, with detection rates of 60.6% and 28.9%., Conclusions: This study shows that neonatal sepsis caused by Klebsiella pneumoniae infection has a high incidence and drug resistance in premature and low birth weight infants, and has become a serious public health problem; Clinicians should pay attention to differential diagnosis, Reasonable selection of antibiotics to reduce the generation of drug-resistant bacteria.
- Published
- 2024
- Full Text
- View/download PDF
18. Exploring factors influencing delayed first antibiotic treatment for suspected early-onset sepsis in preterm newborns: a study before quality improvement initiative.
- Author
-
Chen J, Fang X, Liu W, Huang C, and Dai Y
- Subjects
- Humans, Infant, Newborn, Retrospective Studies, Female, Male, China, Linear Models, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Infant, Premature, Time-to-Treatment, Neonatal Sepsis drug therapy, Neonatal Sepsis diagnosis, Quality Improvement
- Abstract
Background: Early-onset sepsis (EOS) is a serious illness that affects preterm newborns, and delayed antibiotic initiation may increase the risk of adverse outcomes., Purpose: The objective of this study was to examine the present time of antibiotic administration in preterm infants with suspected EOS and the factors that contribute to delayed antibiotic initiation., Methods: In this retrospective study in China, a total of 82 early preterm infants with suspected EOS between December 2021 and March 2023 were included. The study utilized a linear regression analytical approach to identify independent factors that contribute to delayed antibiotic administration., Results: The mean gestational age and birth weight of the study population were 29.1 ± 1.4 weeks and 1265.7 ± 176.8 g, respectively. The median time of initial antibiotic administration was 3.8 (3.1-5.0) hours. Linear regression revealed that severe respiratory distress syndrome (RDS) (β = 0.07, P = 0.013), penicillin skin test (PST) timing (β = 0.06, P < 0.001) and medical order timing (β = 0.04, P = 0.017) were significantly associated with the initial timing of antibiotic administration., Conclusions: There is an evident delay in antibiotic administration in preterm infants with suspected EOS in our unit. Severe RDS, PST postponement and delayed medical orders were found to be associated with the delayed use of antibiotics, which will be helpful for quality improvement efforts in the neonatal intensive care unit (NICU)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. Challenges and opportunities in neonatal sepsis management: insights from a survey among clinicians in 25 Sub-Saharan African countries.
- Author
-
Rosa-Mangeret F, Dupuis M, Dewez JE, Muhe LM, Wagner N, and Pfister RE
- Subjects
- Humans, Infant, Newborn, Africa South of the Sahara epidemiology, Surveys and Questionnaires, Practice Patterns, Physicians' statistics & numerical data, Male, Female, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis diagnosis, Neonatal Sepsis epidemiology, Neonatal Sepsis drug therapy
- Abstract
Background: Neonatal sepsis (NS) is a global health issue, particularly in Sub-Saharan Africa, where it accounts for a substantial portion of neonatal morbimortality. This multicountry survey aimed to elucidate current practices, challenges and case definitions in managing NS among clinicians in Sub-Saharan Africa., Methods: The survey targeted physicians and medical practitioners working in neonatal care who participated in a Self-Administered Web Questionnaire. The main objective was to understand NS and infection case definitions and management from the clinician's point of view and to identify challenges and opportunities in sepsis management. Participants were queried on demographics, definitions and diagnostic criteria, treatment approaches, and infection prevention and control (IPC) measures. A total of 136 participants from 93 healthcare structures responded, providing valuable insights into NS management practices., Results: From May to July 2022 across 21 Sub-Saharan African countries, 136 neonatal clinicians with an average from 93 structures with on average 10-year experience took the survey. NS ranked highest among prevalent neonatal conditions. Diagnostic case definitions between sepsis and infection were attributed to clinical signs, anamnesis, C reactive protein, white blood cll count and blood cultures with no statistically significant differences. Early-onset sepsis was defined within 72 hours by 48%, while late-onset varied. Antibiotics were likely on admission (86.4%) and during the stay (82.2%). Treatment abandonment was reported unlikely. The preferred antibiotic regimen for early-onset sepsis was intravenous amoxicillin (or ampicillin), gentamycin and cefotaxime. Blood culture availability and IPC protocols were reported as limited, particularly concerning patient environment, pharmacy protocols and clean-dirty circuits., Conclusions: This NS survey emphasises clinicians' challenges due to limited access to diagnostic tools and raises concerns about antimicrobial overexposure. IPC also seem limited, according to participants. Addressing these challenges can enhance diagnostic practices, antibiotic stewardship and infection control in the region., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
20. Use of the "Sepsis Risk Calculator" in Belgian Newborns: A Retrospective Cohort Study.
- Author
-
Langer BI, Johansson AB, Mathé K, Jourdain S, and Smeesters PR
- Subjects
- Humans, Infant, Newborn, Retrospective Studies, Belgium epidemiology, Risk Assessment, Female, Male, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis epidemiology, Neonatal Sepsis drug therapy, Neonatal Sepsis prevention & control
- Abstract
Background: Prevention of early-onset neonatal sepsis (EONS) is a frequent reason why many newborns receive unnecessary antibiotics. The Sepsis Risk Calculator (SRC) was developed by the Kaiser Permanente Institute as a multivariate risk assessment of EONS, aiming to reduce laboratory testing and empiric neonatal antibiotic therapy. Our objective was to assess the potential of the SRC in reducing antibiotic use in our setting., Methods: Late preterm and term newborns who received antibiotics from 2019 to 2020 in a tertiary Belgian hospital were included. Newborn-specific data were collected and entered into the online SRC, retrospectively calculating a sepsis risk score and providing recommendations for antibiotic administration. False-positive indications for treatment by the SRC were estimated based on previously published data. Antibiotic therapy rates according to the SRC recommendations were compared to the actual rate of antibiotic therapy., Results: Of 5891 births, 414 newborns received antibiotics and were eligible for this study, representing a rate of 7.6% of newborns receiving antibiotics following our current guidelines. The SRC would have recommended antibiotic administration for 2.7%, reducing antibiotic therapy by 64.5%. Of 5 possible cases of EONS, 3 would have received antibiotics in the first 24 hours according to the SRC., Conclusions: In this Belgian cohort, use of the SRC has the potential to significantly decrease by 64.5% the newborns that receive antibiotics. This reduction would primarily concern asymptomatic newborns. If use of the SRC was to be implemented in Belgian maternities, strict clinical surveillance practices should be ensured., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Antimicrobial Stewardship Programs in Neonates: A Meta-Analysis.
- Author
-
Mascarenhas D, Ho MSP, Ting J, and Shah PS
- Subjects
- Humans, Infant, Newborn, Neonatal Sepsis drug therapy, Anti-Bacterial Agents therapeutic use, Cost-Benefit Analysis, Intensive Care Units, Neonatal, Antimicrobial Stewardship
- Abstract
Background and Objectives: Neonatal sepsis is a significant contributor to mortality and morbidity; however, the uncontrolled use of antimicrobials is associated with significant adverse effects. Our objective with this article is to review the components of neonatal antimicrobial stewardship programs (ASP) and their effects on clinical outcomes, cost-effectiveness, and antimicrobial resistance., Methods: We selected randomized and nonrandomized trials and observational and quality improvement studies evaluating the impact of ASP with a cutoff date of May 22, 2023. The data sources for these studies included PubMed, Medline, Embase, Cochrane CENTRAL, Web of Science, and SCOPUS. Details of the ASP components and clinical outcomes were extracted into a predefined form., Results: Of the 4048 studies retrieved, 70 studies (44 cohort and 26 observational studies) of >350 000 neonates met the inclusion criteria. Moderate-certainty evidence reveals a significant reduction in antimicrobial initiation in NICU (pooled risk difference [RD] 19%; 95% confidence interval [CI] 14% to 24%; 21 studies, 27 075 infants) and combined NICU and postnatal ward settings (pooled RD 8%; 95% CI 6% to 10%; 12 studies, 358 317 infants), duration of antimicrobial agents therapy (pooled RD 20%; 95% CI 10% to 30%; 9 studies, 303 604 infants), length of therapy (pooled RD 1.82 days; 95% CI 1.09 to 2.56 days; 10 studies, 157 553 infants), and use of antimicrobial agents >5 days (pooled RD 9%; 95% CI 3% to 15%; 5 studies, 9412 infants). Low-certainty evidence reveals a reduction in economic burden and drug resistance, favorable sustainability metrices, without an increase in sepsis-related mortality or the reinitiation of antimicrobial agents. Studies had heterogeneity with significant variations in ASP interventions, population settings, and outcome definitions., Conclusions: Moderate- to low-certainty evidence reveals that neonatal ASP interventions are associated with reduction in the initiation and duration of antimicrobial use, without an increase in adverse events., (Copyright © 2024 by the American Academy of Pediatrics.)
- Published
- 2024
- Full Text
- View/download PDF
22. Early-onset neonatal sepsis: Effectiveness of classification based on ante- and intrapartum risk factors and clinical monitoring.
- Author
-
Dalut L, Brunhes A, Cambier S, Gallot D, and Coste K
- Subjects
- Humans, Infant, Newborn, Risk Factors, Female, Pregnancy, France epidemiology, Male, Practice Guidelines as Topic, Clinical Protocols standards, Neonatal Sepsis drug therapy, Anti-Bacterial Agents therapeutic use
- Abstract
Introduction: In 2017, the French public health authority HAS published new guidelines for the management of newborns at risk of early bacterial neonatal infection. These guidelines were based on ante- and intrapartum risk factors and clinical monitoring. In January 2021, we implemented a new protocol based on these guidelines in our tertiary maternity unit., Objectives: To assess the impact of the protocol implemented on neonates' antibiotic prescriptions., Method: An "old protocol" group comprising newborns hospitalized between July 1, 2020 and December 31, 2020, was compared to a "new protocol" group formed between January 14, 2021 and July 13, 2021. Data were collected on infectious risk factors, antibiotic prescriptions, and emergency room visits within 2 weeks for an infection or suspected infection., Results: The "old protocol" population comprised 1565 children and the "new protocol" population 1513. Antibiotic therapy was prescribed for 29 newborns (1.85 %) in the old protocol group versus 15 (0.99 %) in the new one (p = 0.05). The median duration was 5 days and 2 days respectively (p = 0.08). With the new protocol, newborns in category B were about 20 times more likely (p = 0.01), and those in category C about 54 times more likely (p = 0.005) to have an infection than those classified in categories N or A., Conclusion: This study demonstrates that clinical monitoring criteria enable reduced use and duration of antibiotic therapy and are reliable., Competing Interests: Declaration of competing interest The authors declare that they have no competing interest., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Differential Abundances of Bdellovibrio and Rheinheimera in the Oral Microbiota of Neonates With and Without Clinical Sepsis.
- Author
-
Thatrimontrichai A, Surachat K, Singkhamanan K, and Thongsuksai P
- Subjects
- Humans, Infant, Newborn, Female, Male, Infant, Very Low Birth Weight, Milk, Human microbiology, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Mouth microbiology, Microbiota drug effects
- Abstract
Background: Neonatal sepsis is associated with high rates of morbidity and mortality, long hospital stays and high cost of care, thereby inflicting a burden on health care systems. Oral care with breast milk has been shown to modify the intestinal tract microbiota and immune system. Herein, we attempted to identify probiotics that may be beneficial to prevent or treat neonatal sepsis., Methods: This was a secondary analysis comparing the microbiota during oropharyngeal care in very-low-birth-weight infants with and without clinical sepsis. Oral samples were collected before oral feeding was initiated. The primary outcome was oral microbiota composition including diversity, relative abundance and linear discriminant analysis effect size., Results: Sixty-three neonates, including 39 and 24 with and without clinical sepsis, respectively, were enrolled. The medians gestational age and birth weight were 29 (27-30) weeks and 1010 (808-1263) g. Neonates with clinical sepsis had lower gestational age, birth weight (both P < 0.001) and lower rate of oral care with breast milk ( P = 0.03), but higher doses and days of antibiotic exposure (both P < 0.001) compared to neonates without clinical sepsis. No differences in alpha and beta diversities were found between groups and Streptococcus agalactiae was the most common bacteria in both groups. Linear discriminant analysis effect size analysis revealed that neonates without clinical sepsis had significantly higher abundances of order Bdellovibrionales, family Bdellovibrionaceae, genus Bdellovibrio and genus Rheinheimera ., Conclusions: Neonates without clinical sepsis had a significantly greater abundance of the Bdellovibrio and Rheinheimera genera., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. [Advances in clinical management of neonatal sepsis].
- Author
-
Yu YQ and Chen PY
- Subjects
- Humans, Infant, Newborn, Risk Factors, Neonatal Sepsis therapy, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy
- Abstract
Neonatal sepsis, as a significant cause of various complications and adverse outcomes in neonates, remains a serious health burden both domestically and internationally. Strategies such as antibiotic prophylaxis during delivery, the utilization of early-onset sepsis risk calculators, and quality improvement initiatives in neonatal wards are beneficial in alleviating the disease burden of neonatal sepsis. This paper provides a review of the epidemiology, risk factors, and recent advances in clinical management of neonatal sepsis.
- Published
- 2024
- Full Text
- View/download PDF
25. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.
- Author
-
Kakaraskoska Boceska B, Vilken T, Xavier BB, Kostyanev T, Lin Q, Lammens C, Ellis S, O'Brien S, da Costa RMA, Cook A, Russell N, Bielicki J, Riddell A, Stohr W, Walker AS, Berezin EN, Roilides E, De Luca M, Romani L, Ballot D, Dramowski A, Wadula J, Lochindarat S, Boonkasidecha S, Namiiro F, Ngoc HTB, Tran MD, Cressey TR, Preedisripipat K, Berkley JA, Musyimi R, Zarras C, Nana T, Whitelaw A, da Silva CB, Jaglal P, Ssengooba W, Saha SK, Islam MS, Mussi-Pinhata MM, Carvalheiro CG, Piddock LJV, Heath PT, Malhotra-Kumar S, Sharland M, Glupczynski Y, and Goossens H
- Subjects
- Humans, Infant, Newborn, Amikacin pharmacology, Amikacin therapeutic use, Fosfomycin pharmacology, Fosfomycin therapeutic use, beta-Lactamases genetics, beta-Lactamases metabolism, Escherichia coli drug effects, Escherichia coli genetics, Escherichia coli isolation & purification, Developing Countries, Drug Resistance, Multiple, Bacterial genetics, Drug Therapy, Combination, Serratia marcescens drug effects, Serratia marcescens genetics, Serratia marcescens isolation & purification, Enterobacter cloacae drug effects, Enterobacter cloacae genetics, Enterobacter cloacae isolation & purification, Bacterial Proteins genetics, Bacterial Proteins metabolism, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria genetics, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections microbiology, Acinetobacter baumannii drug effects, Acinetobacter baumannii isolation & purification, Acinetobacter baumannii genetics, Microbial Sensitivity Tests, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae isolation & purification, Klebsiella pneumoniae genetics
- Abstract
Gram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs. The five most prevalent bacterial isolates in the NeoOBS study (NCT03721302) are Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, Serratia marcescens and Enterobacter cloacae complex. Among these isolates, high levels of ESBL and carbapenemase encoding genes are detected along with resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens. The three new combinations show excellent in vitro activity against ESBL-producing K. pneumoniae and E. coli isolates. Our data should further inform and support the clinical evaluation of these three antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-resistant Gram-negative bacteria., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Early procalcitonin assays may reduce antibiotic exposure in premature newborn infants.
- Author
-
Hue-Bigé A, François-Garret B, Casagrande F, Oertel J, Mayerus M, and Eleni Dit Trolli S
- Subjects
- Infant, Newborn, Infant, Humans, Procalcitonin, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Infant, Newborn, Diseases, Sepsis diagnosis, Sepsis drug therapy
- Abstract
Aim: The diagnosis of early-onset neonatal sepsis (EOS) remains difficult. The main aim was to study the effect of a new algorithm for EOS, which includes the level of procalcitonin in umbilical cord blood, on the exposure to antibiotic therapy of premature newborn infants., Methods: This was a monocentric, observational and retrospective study with before-and-after design. The duration and dose of antibiotic therapy provided as well as the morbidity and mortality were compared in two groups, one included 01 May 2015-30 November 2015 when procalcitonin was not used, and one after the change 01 November 2016-30 May 2017 when procalcitonin was used in a hospital setting in Nice, France., Results: Sixty newborn infants were included in the before group and 54 in the after group. Antibiotic therapy was stopped after 24 h for 18 newborn infants in the after group and four in the before group, and after 48 h for 26 newborn infants in the after group and 10 in the before group., Conclusion: The implementation of a new decision-making algorithm including early procalcitonin assay of premature newborn infants significantly reduced exposure to antibiotics without modifying mortality or morbidity., (© 2024 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.)
- Published
- 2024
- Full Text
- View/download PDF
27. A Neonatologist-Driven Antimicrobial Stewardship Program in a Neonatal Tertiary Care Center in Oman.
- Author
-
Malviya MN, Murthi S, Selim AA, Malik F, Jayraj D, Mendoza J, Ramdas V, Rasheed S, Jabri AA, Sabri RA, Asiry SA, Yahmadi MA, and Shah PS
- Subjects
- Humans, Infant, Newborn, Oman, Retrospective Studies, Male, Female, Neonatologists, Neonatal Sepsis drug therapy, Intensive Care Units, Neonatal, Antimicrobial Stewardship organization & administration, Tertiary Care Centers, Anti-Bacterial Agents therapeutic use
- Abstract
Objective: The overuse of antimicrobials in neonates is not uncommon and has resulted in a global health crisis of antibiotic resistance. This study aimed to evaluate changes associated with a neonatologist-driven antimicrobial stewardship program (ASP) in antibiotic usage., Study Design: We conducted a pre-post retrospective cohort study in a tertiary care hospital in Oman. Neonates admitted in 2014 to 2015 were considered as the pre-ASP cohort. In 2016, a neonatologist-driven ASP was launched in the unit. The program included the optimization and standardization of antibiotic use for early- and late-onset sepsis using the Centers for Disease Control and Prevention's "broad principles," an advanced antimicrobial decision-support system to resolve contentious issues, and placed greater emphasis on education and behavior modification. Data from the years 2016 to 2019 were compared with previous data. The outcome of interest included days of therapy (DOT) for antimicrobials. Baseline characteristics and outcomes were compared using standard statistical measures., Results: The study included 2,098 neonates in the pre-ASP period and 5,464 neonates in the post-ASP period. There was no difference in baseline characteristics. The antibiotic use decreased from 752 DOT per 1,000 patient-days (PD) in the pre-ASP period to 264 DOT in the post-ASP period (64.8% reduction, p < 0.001). The proportion of neonates who received any antibiotics declined by 46% (pre-ASP = 1,161/2,098, post-ASP = 1,676/5,464). The most statistically significant reduction in DOT per 1,000 PD was observed in the use of cefotaxime (82%), meropenem (74%), and piperacillin-tazobactam (74%). There was no change in mortality, culture-positive microbial profile, or multidrug-resistant organism incidence in the post-ASP period., Conclusion: Empowering frontline neonatologists to drive ASPs was associated with a sustained reduction in antibiotic utilization., Key Points: · Overuse of antimicrobials is not uncommon in neonatal intensive care units.. · ASPs and infection control and prevention measures may help in decreasing antibiotic consumption and culture-positive sepsis.. · Empowering frontline neonatologists resulted in a sustained decrease in antimicrobial use without extra resources or financial burden.., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Interstate Practice Variation and Factors Associated with Antibiotic Use for Suspected Neonatal Sepsis in the United States.
- Author
-
Vidavalur R and Hussain N
- Subjects
- Humans, Infant, Newborn, United States epidemiology, Female, Cross-Sectional Studies, Retrospective Studies, Male, Gestational Age, Pregnancy, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Anti-Bacterial Agents therapeutic use, Practice Patterns, Physicians' statistics & numerical data, Chorioamnionitis epidemiology, Chorioamnionitis drug therapy
- Abstract
Objective: This study aimed to estimate national time trends of overall and statewise antibiotic utilization (AU) rates for suspected neonatal sepsis (SNS) in the United States., Study Design: In this cross-sectional study, we used retrospective linked birth cohort and vital records data from the Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research database for the years 2016 to 2020 and analyzed data containing antibiotic use for SNS. The primary outcome was proportional national and state-specific AU rates per 1,000 live births during the birth hospitalization. Secondary outcomes included overall trends and association between maternal education, race, sex, chorioamnionitis, mode of delivery, gestational age at birth, Apgar's scores, and insurance status with antibiotics exposure for SNS among newborns. Contingency tables, two-tailed t -test, and chi-square for independence tests were performed with statistical significance set at p < 0.05., Results: For a birth cohort of >18 million, 2.2% of infants received antibiotics during birth hospitalization nationwide. There were wide variations in AU among U.S. states and territories, whereas overall treatment rates decreased by 16.1% (95% confidence interval [CI]: 15.2-17.0; p < 0.001). Compared with White newborns, Black newborns had higher AU rates (odds ratio [OR]: 1.33; 95% CI: 1.32-1.34), and Asians had the lowest rates (OR: 0.96; 95% CI: 0.95-0.97). There was a significant difference in mean AU rates by race ( p < 0.001). Chorioamnionitis at birth significantly increased the odds for AU (OR: 14.5 ;95% CI: 14.4-14.6), although AU rates for chorioamnionitis showed a significant downward trend (OR: 0.52; 95% CI: 0.50-0.53) during the study period., Conclusion: Our findings suggest that there has been a gradual decline in AU for SNS in more than a third of states in last 5 years. While risk-based management approaches achieve widespread implementation, state- and nationwide quality improvement collaborates might have contributed to the relative decline in antibiotic use in newborns. Further studies are warranted to understand factors related to practice variation in the management of SNS in the United States KEY POINTS: · Early and prolonged use of antibiotics can lead to altered gut microbiome and adverse long-term neonatal outcomes.. · There is considerable clinical practice variation in antibiotic-prescribing practices for suspected neonatal sepsis.. · This cross-sectional study reports the differences in neonatal antibiotic usage patterns by region and maternal factors.. · Antibiotic use should be limited to newborns at high risk of infection and proven sepsis.. · Judicious use of antibiotics can be promoted by following evidence-based approaches to sepsis risk assessment.., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Utility of the Neonatal Early-Onset Sepsis Calculator in a Low-Risk Population.
- Author
-
Sonney KM, Tomasini D, Aden JK, and Drumm CM
- Subjects
- Humans, Infant, Newborn, Retrospective Studies, Female, Risk Assessment, Male, Cesarean Section, Blood Culture, Infant, Premature, Gestational Age, Pregnancy, Risk Factors, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Anti-Bacterial Agents therapeutic use
- Abstract
Objective: To compare early-onset sepsis (EOS) risk estimation and recommendations for infectious evaluation and/or empiric antibiotics using a categorical risk assessment versus the Neonatal Early-Onset Sepsis Calculator in a low-risk population., Study Design: Retrospective chart review of late preterm (≥35
0/7 -366/7 weeks' gestational age) and term infants born at the Brooke Army Medical Center between January 1, 2012 and August 29, 2019. We evaluated those born via cesarean section with rupture of membranes (ROM) < 10 minutes. Statistical analysis was performed to compare recommendations from a categorical risk assessment versus the calculator., Results: We identified 1,187 infants who met inclusion criteria. A blood culture was obtained within 72 hours after birth from 234 (19.7%) infants and 170 (14.3%) received antibiotics per routine clinical practice, using categorical risk assessment. Respiratory distress was the most common indication for evaluation, occurring in 173 (14.6%) of patients. After applying the Neonatal Early-Onset Sepsis Calculator to this population, the recommendation was to obtain a blood culture on 166 (14%), to start or strongly consider starting empiric antibiotics on 164 (13.8%), and no culture or antibiotics on 1,021 (86%). Utilizing calculator recommendations would have led to a reduction in frequency of blood culture (19.7 vs. 14%, p < 0.0001) but no reduction in empiric antibiotics (14.3 vs. 13.8%, p = 0.53). There were no cases of culture-proven EOS., Conclusion: This population is low risk for development of EOS; however, 19.7% received an evaluation for infection and 14.3% received antibiotics. Utilization of the Neonatal Early-Onset Sepsis Risk Calculator would have led to a significant reduction in the evaluation for EOS but no reduction in antibiotic exposure. Consideration of delivery mode and indication for delivery may be beneficial to include in risk assessments for EOS., Key Points: · Cesarean section with rupture of membranes at delivery confers low risk for EOS.. · Respiratory distress often triggers an EOS evaluation.. · Delivery mode should be considered in EOS risk.., Competing Interests: The views expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, or the Department of Defense, nor any agencies under the U.S. Government., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)- Published
- 2024
- Full Text
- View/download PDF
30. Antibiotic use in infants at risk of early-onset sepsis: results from a unicentric retrospective cohort study.
- Author
-
Morales-Betancourt C, Fontiveros-Escalona D, Montealegre-Pomar A, Carbayo-Jiménez T, Palomares-Eraso M, de Alba-Romero C, Bergón-Sendín E, Moral Pumarega MT, and Pallás-Alonso C
- Subjects
- Infant, Newborn, Infant, Humans, Anti-Bacterial Agents therapeutic use, Retrospective Studies, Sepsis drug therapy, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy
- Abstract
Background: Antibiotic use for early-onset sepsis represents a high percentage of antibiotic consumption in the neonatal setting. Measures to assess infants at risk of early-onset sepsis are needed to optimize antibiotic use. Our primary objective was to assess the impact of a departmental guideline on antibiotic use among term infants with suspected EOS not confirmed, in our neonatal unit., Methods: Retrospective cohort study, to compare antibiotic use in term infants during a baseline period of January to December 2018, and a postintervention period from October 2019, to September 2020, respectively. The primary outcome was antibiotic use measured by days of therapy, the antibiotic spectrum index, the antibiotic use rate, and the length of therapy., Results: We included 71 infants in the baseline period and 66 infants in the postintervention period. Compared to those in the baseline period, there was a significant reduction in overall antibiotic measures in the postintervention period, (P < 0.001). The total days of therapy/1000 patient-days decreased from 63/1000 patient-days during the baseline period to 25.8/1000 patient-days in the postintervention period, representing a relative reduction of 59%. The antibiotic use rate decreased by more than half of the infants, from 3.2% during the baseline period to 1.3% in the postintervention period., Conclusions: The use of a departmental guideline to assess infants at risk of early-onset sepsis based on their clinical condition and prompt discontinuation of antibiotics, is a simple and low-cost measure that contributed to an important decrease in antibiotic use., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
31. Reducing intravenous antibiotics in neonates born ≥35 weeks' gestation: A quality improvement study.
- Author
-
Grace E, Jayakumar N, Cooper C, Andersen C, Callander E, Gomersall J, Rumbold A, and Keir A
- Subjects
- Humans, Infant, Newborn, Retrospective Studies, Female, Prospective Studies, Male, Neonatal Sepsis drug therapy, Gestational Age, Length of Stay statistics & numerical data, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Quality Improvement, Administration, Intravenous
- Abstract
Aim: To assess the impact of the Early Onset Sepsis (EOS) calculator, implemented as a quality improvement study, to reduce the rate of unnecessary antibiotics in neonates born ≥35 weeks' gestation., Methods: An audit of routinely collected hospital data from January 2008 to March 2014 (retrospective) and from January 2018 to September 2019 (prospective) determined baseline incidence of EOS intravenous antibiotic use in neonates born ≥35 weeks' gestation in a tertiary level perinatal centre. Plan-do-study-act (PDSA) cycles were applied to implement the EOS calculator. Statistical process control methodology and time series analysis assessments were used to assess the potential impact of the PDSA cycles on the rate of intravenous antibiotics, blood culture collection, EOS, length of stay and health care costs (not adjusted for potential confounders)., Results: In the study population, from January 2008 to March 2014, the baseline incidence of intravenous antibiotic use was 10.49% (2970/28290), whilst only 0.067% (19/28290) neonates had culture proven EOS. From January 2018 to October 2019, prior to implementation of the EOS calculator, 13.3% (1119/8411) neonates were treated with intravenous antibiotic and the use decreased to 8.3% (61/734) post-implementation. The rate of blood culture collection decreased from 14.4% (1211/8411) to 11.9% (87/734). There were no cases of missed EOS. Length of stay decreased from 2.68 to 2.39 days, with an estimated cost saving of $366 per patient per admission., Conclusion: Implementing the EOS calculator in a tertiary hospital setting reduced invasive investigations for EOS and intravenous antibiotic use among neonates ≥35 weeks' gestation. This can result in reduced length of neonatal hospital stays, and associated health care cost savings and may reduce separation of mother and baby., (© 2024 The Authors. Journal of Paediatrics and Child Health published by John Wiley & Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).)
- Published
- 2024
- Full Text
- View/download PDF
32. Population pharmacokinetics of ciprofloxacin in newborns with early onset neonatal sepsis and suspected meningitis.
- Author
-
Garg K, Bhandari RK, Shafiq N, Jain S, Jaswal S, Chawla D, Mallayasamy S, Khurana S, and Batcha JSD
- Subjects
- Humans, Infant, Newborn, Female, Male, Meningitis drug therapy, Meningitis cerebrospinal fluid, Models, Biological, Chromatography, High Pressure Liquid, Administration, Intravenous, Ciprofloxacin pharmacokinetics, Ciprofloxacin administration & dosage, Ciprofloxacin blood, Neonatal Sepsis drug therapy, Neonatal Sepsis blood, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents blood
- Abstract
Background: Neonatal Sepsis accounts for significant proportion of neonatal mortality globally. Ciprofloxacin can be used as an effective antimicrobial against common causative agents of neonatal sepsis. However, there is only limited information about its pharmacokinetic distribution in plasma and Cerebrospinal fluid (CSF) of neonates., Methods: Plasma and CSF samples were taken using a sparse sampling technique from neonates who received at least one dose of intravenous ciprofloxacin. Ciprofloxacin levels were analysed using high-performance liquid chromatography (HPLC). Population pharmacokinetic analysis was conducted using a non-linear mixed-effects modelling using Pumas® (Pharmaceutical Modelling and Simulation) package (Version 2.0)., Results: 53 neonates were enroled in the study of whom; 9 (17%) had meningitis. The median concentration of ciprofloxacin in CSF was 1.4 (0.94-2.06) ug/ml and plasma was 2.94 (1.8-5.0) ug/ml. A one-compartment model with first-order elimination fitted the data. Body weight was found to be a significant covariate on volume of distribution (Vd). Simulations based on the final model suggest that dose of 10 mg/kg, intravenous b.d may not be able to achieve the desirable indices., Conclusions: One compartment model with weight as a covariate explained the available data. Further studies with modified sampling strategy, larger sample size and variable dose levels are needed., (© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
33. Stenotrophomonas maltophilia neonatal sepsis: a case report.
- Author
-
Adefila WO, Osie I, Keita ML, Wutor BM, Yusuf AO, Hossain I, Molfa M, Barjo O, Salaudeen R, and Mackenzie G
- Subjects
- Child, Infant, Newborn, Male, Humans, Anti-Bacterial Agents therapeutic use, Gentamicins therapeutic use, Stenotrophomonas maltophilia, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Gram-Negative Bacterial Infections diagnosis, Gram-Negative Bacterial Infections drug therapy
- Abstract
Background: Stenotrophomonas maltophilia is a gram-negative bacteria known for causing opportunistic and nosocomial infections in humans. S. maltophilia is an emerging pathogen of concern due to it's increasing prevalence, diverse disease spectrum, intrinsic multi-drug resistance and high mortality rates in immunocompromised individuals. S. maltophilia is a rare cause of neonatal sepsis associated with significant morbidity and mortality. The bacterium's multi-drug resistance poses a considerable challenge for treatment, with various mechanisms contributing to its resistance., Case Presentation: We report a case involving a 40-h-old male African neonate who exhibited symptoms of neonatal sepsis. The blood culture revealed Stenotrophomonas maltophilia, which was sensitive to ciprofloxacin and gentamicin but resistant to other antibiotics. Lumbar puncture for CSF could not be done because the father declined. We treated the newborn with the empirical first-line antibiotics as per the national guideline intravenous ampicillin and gentamicin for six days, and the child recovered fully with a repeated negative blood culture., Conclusions: This report describes a neonatal sepsis case caused by S. maltophilia, a multi-drug resistant bacteria and a rare cause of neonatal sepsis. We report that early detection of the bacterial and antimicrobial management based on local antibiogram data may be essential for successful patient's management., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
34. Clinical chorioamnionitis at term: definition, pathogenesis, microbiology, diagnosis, and treatment.
- Author
-
Jung E, Romero R, Suksai M, Gotsch F, Chaemsaithong P, Erez O, Conde-Agudelo A, Gomez-Lopez N, Berry SM, Meyyazhagan A, and Yoon BH
- Subjects
- Female, Infant, Newborn, Pregnancy, Humans, Clarithromycin therapeutic use, Anti-Bacterial Agents therapeutic use, Amniotic Fluid microbiology, Inflammation metabolism, Tachycardia, Chorioamnionitis diagnosis, Chorioamnionitis drug therapy, Chorioamnionitis etiology, Postpartum Hemorrhage drug therapy, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy
- Abstract
Clinical chorioamnionitis, the most common infection-related diagnosis in labor and delivery units, is an antecedent of puerperal infection and neonatal sepsis. The condition is suspected when intrapartum fever is associated with two other maternal and fetal signs of local or systemic inflammation (eg, maternal tachycardia, uterine tenderness, maternal leukocytosis, malodorous vaginal discharge or amniotic fluid, and fetal tachycardia). Clinical chorioamnionitis is a syndrome caused by intraamniotic infection, sterile intraamniotic inflammation (inflammation without bacteria), or systemic maternal inflammation induced by epidural analgesia. In cases of uncertainty, a definitive diagnosis can be made by analyzing amniotic fluid with methods to detect bacteria (Gram stain, culture, or microbial nucleic acid) and inflammation (white blood cell count, glucose concentration, interleukin-6, interleukin-8, matrix metalloproteinase-8). The most common microorganisms are Ureaplasma species, and polymicrobial infections occur in 70% of cases. The fetal attack rate is low, and the rate of positive neonatal blood cultures ranges between 0.2% and 4%. Intrapartum antibiotic administration is the standard treatment to reduce neonatal sepsis. Treatment with ampicillin and gentamicin have been recommended by professional societies, although other antibiotic regimens, eg, cephalosporins, have been used. Given the importance of Ureaplasma species as a cause of intraamniotic infection, consideration needs to be given to the administration of antimicrobial agents effective against these microorganisms such as azithromycin or clarithromycin. We have used the combination of ceftriaxone, clarithromycin, and metronidazole, which has been shown to eradicate intraamniotic infection with microbiologic studies. Routine testing of neonates born to affected mothers for genital mycoplasmas could improve the detection of neonatal sepsis. Clinical chorioamnionitis is associated with decreased uterine activity, failure to progress in labor, and postpartum hemorrhage; however, clinical chorioamnionitis by itself is not an indication for cesarean delivery. Oxytocin is often administered for labor augmentation, and it is prudent to have uterotonic agents at hand to manage postpartum hemorrhage. Infants born to mothers with clinical chorioamnionitis near term are at risk for early-onset neonatal sepsis and for long-term disability such as cerebral palsy. A frontier is the noninvasive assessment of amniotic fluid to diagnose intraamniotic inflammation with a transcervical amniotic fluid collector and a rapid bedside test for IL-8 for patients with ruptured membranes. This approach promises to improve diagnostic accuracy and to provide a basis for antimicrobial administration., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
35. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
- Author
-
Darlow CA, Parrott N, Peck RW, and Hope W
- Subjects
- Humans, Infant, Newborn, Amikacin pharmacokinetics, Anti-Bacterial Agents pharmacokinetics, Microbial Sensitivity Tests, Multicenter Studies as Topic, Clinical Trials as Topic, Fosfomycin pharmacokinetics, Neonatal Sepsis drug therapy
- Abstract
Antimicrobial resistance increasingly complicates neonatal sepsis in a global context. Fosfomycin and amikacin are two agents being tested in an ongoing multicenter neonatal sepsis trial. Although neonatal pharmacokinetics (PKs) have been described for these drugs, the physiological variability within neonatal populations makes population PKs in this group uncertain. Physiologically-based pharmacokinetic (PBPK) models were developed in Simcyp for fosfomycin and amikacin sequentially for adult, pediatric, and neonatal populations, with visual and quantitative validation compared to observed data at each stage. Simulations were performed using the final validated neonatal models to determine drug exposures for each drug across a demographic range, with probability of target attainment (PTA) assessments. Successfully validated neonatal PBPK models were developed for both fosfomycin and amikacin. PTA analysis demonstrated high probability of target attainment for amikacin 15 mg/kg i.v. q24h and fosfomycin 100 mg/kg (in neonates aged 0-7 days) or 150 mg/kg (in neonates aged 7-28 days) i.v. q12h for Enterobacterales with fosfomycin and amikacin minimum inhibitory concentrations at the adult breakpoints. Repeat analysis in premature populations demonstrated the same result. PTA analysis for a proposed combination fosfomycin-amikacin target was also performed. The simulated regimens, tested in a neonatal sepsis trial, are likely to be adequate for neonates across different postnatal ages and gestational age. This work demonstrates a template for determining target attainment for antimicrobials (alone or in combination) in special populations without sufficient available PK data to otherwise assess with traditional pharmacometric methods., (© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
36. Risk factors of multidrug-resistant organisms neonatal sepsis in Surabaya tertiary referral hospital: a single-center study.
- Author
-
Miranda S, Harahap A, Husada D, and Faramarisa FN
- Subjects
- Infant, Newborn, Female, Humans, Drug Resistance, Multiple, Bacterial, Tertiary Care Centers, Cross-Sectional Studies, Anti-Bacterial Agents therapeutic use, Risk Factors, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Sepsis complications, Infant, Newborn, Diseases, Pregnancy Complications drug therapy, Fetal Membranes, Premature Rupture drug therapy
- Abstract
Background: Bacterial organisms causing neonatal sepsis have developed increased resistance to commonly used antibiotics. Antimicrobial resistance is a major global health problem. The spread of Multidrug-Resistant Organisms (MDROs) is associated with higher morbidity and mortality rates. This study aimed to determine the risk factors for developing MDRO neonatal sepsis in the Neonatal Intensive Care Unit (NICU), dr. Ramelan Navy Central Hospital, in 2020-2022., Methods: A cross-sectional study was performed on 113 eligible neonates. Patients whose blood cultures were positive for bacterial growth and diagnosed with sepsis were selected as the study sample. Univariate and multivariate analysis with multiple logistic regression were performed to find the associated risk factors for developing multidrug-resistant organism neonatal sepsis. A p-value of < 0.05 was considered significant., Results: Multidrug-resistant organisms were the predominant aetiology of neonatal sepsis (91/113, 80.5%). The significant risk factors for developing MDRO neonatal sepsis were lower birth weight (OR: 1.607, 95% CI: 1.003 - 2.576, p-value: 0.049), history of premature rupture of the membrane (ProM) ≥ 18 (OR: 3.333, 95% CI: 2.047 - 5.428, p-value < 0.001), meconium-stained amniotic fluid (OR: 2.37, 95% CI: 1.512 - 3.717, p-value < 0.001), longer hospital stays (OR: 5.067, 95% CI: 2.912 - 8.815, p-value < 0.001), lower Apgar scores (OR: 2.25, 95% CI: 1.442 - 3.512, p-value < 0.001), and the use of respiratory support devices, such as invasive ventilation (OR: 2.687, 95% CI: 1.514 - 4.771, p-value < 0.001), and non-invasive ventilation (OR: 2, 95% CI: 1.097 - 3.645, p-value: 0.024)., Conclusions: Our study determined various risk factors for multidrug-resistance organism neonatal sepsis and underscored the need to improve infection control practices to reduce the existing burden of drug-resistant sepsis. Low-birth-weight, a maternal history of premature rupture of the membrane lasting more than 18 hours, meconium-stained amniotic fluid, longer hospital stays, a low Apgar score, and the use of ventilators were the risk factors for developing drug-resistant neonatal sepsis., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. Impact of adopting a neonatal sepsis risk calculator in a diverse population in Birmingham, UK.
- Author
-
Yew R, Macaskill L, Brown S, Dixie M, Dogar D, Checketts E, and Surana P
- Subjects
- Infant, Newborn, Humans, Infant, Premature, Risk Assessment, United Kingdom epidemiology, Anti-Bacterial Agents therapeutic use, Retrospective Studies, Neonatal Sepsis diagnosis, Neonatal Sepsis epidemiology, Neonatal Sepsis drug therapy, Sepsis diagnosis, Sepsis epidemiology
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
38. [Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)].
- Subjects
- Infant, Newborn, Humans, Meropenem therapeutic use, Neonatal Sepsis drug therapy, Sepsis drug therapy
- Abstract
Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.
- Published
- 2024
- Full Text
- View/download PDF
39. Efficacy and safety of short- vs. standard-course antibiotics for culture-negative neonatal sepsis: a systematic review and meta-analysis.
- Author
-
Devi R, Priyadarshi M, Singh P, Chaurasia S, and Basu S
- Subjects
- Infant, Newborn, Humans, Anti-Bacterial Agents therapeutic use, Length of Stay, Neonatal Sepsis drug therapy, Sepsis drug therapy
- Abstract
Objectives: To conduct a systematic review and meta-analysis of evidence from randomized controlled trials (RCTs) comparing a short course of antibiotics (2-4 days), to a standard course (5-7 days), for the treatment of culture-negative neonatal sepsis., Methods: Relevant databases were searched for RCTs comparing short- vs. standard-course of antibiotics for culture-negative sepsis. The primary outcomes were mortality and treatment failure, defined as the reappearance of clinical signs suggestive of sepsis within 7 days of stoppage of antibiotics. Secondary outcomes included neurological impairment, duration of hospital stay, need for oxygen, respiratory support and double-volume exchange transfusion (DVET)., Results: Seven RCTs were included in the review with 729 neonates >30 weeks gestational age at birth. No mortality occurred in either of the groups (2 studies; 276 neonates). Treatment failure rates were similar in the short- and standard-course antibiotic groups [7 studies; 729 neonates; risk ratio (RR) = 1.01; 95% confidence interval (CI), 0.55 to 1.86; very low certainty]. The short course of antibiotics resulted in a shorter hospital stay [3 studies; 293 neonates; mean difference (MD), -2.46 days; 95% CI, -3.16 to -1.75]. There was no difference in the need for oxygen supplementation (2 studies; 258 neonates; RR, 1.40; 95% CI, 0.40 to 4.91), any respiratory support (2 studies; 258 neonates; RR, 1.04; 95% CI, 0.92 to 1.17) or DVET (2 studies; 258 neonates; RR, 1.29; 95% CI, 0.56 to 2.95)., Conclusion: Very-low certainty evidence suggests that a short antibiotic course, compared to a standard course, does not affect treatment failure rates in culture-negative neonatal sepsis. There is a need for well-designed RCTs powered enough to assess critical outcomes such as mortality and neurological sequelae to generate stronger evidence and inform guidelines., Prospero Registration Number: CRD42023437199., (© The Author(s) [2024]. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
40. Experience With a Vancomycin-sparing Empiric Antibiotic Guideline for Late-onset Sepsis in a Level-4 Neonatal Intensive Care Unit.
- Author
-
Dumont O, Iacono D, Jacob A, Aggarwal A, and Hagmann SHF
- Subjects
- Humans, Infant, Newborn, Methicillin-Resistant Staphylococcus aureus drug effects, Staphylococcal Infections drug therapy, Practice Guidelines as Topic, Retrospective Studies, Neonatal Sepsis drug therapy, Vancomycin therapeutic use, Anti-Bacterial Agents therapeutic use, Intensive Care Units, Neonatal, Sepsis drug therapy
- Abstract
A vancomycin-sparing guideline for suspected late-onset sepsis helped reduce vancomycin usage in our level-4 neonatal intensive care unit. Significant reduction in overall vancomycin use, with its likely unit-wide beneficial downstream effects, may need to be measured against the rare case of methicillin-resistant Staphylococcus aureus infection and delayed effective therapy., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. The effects of antibiotic therapy on neonatal sepsis-associated acute kidney injury.
- Author
-
Pevzner IB, Brezgunova AA, Popkov VA, Sintsov MY, Andrianova NV, Zorova LD, Silachev DN, Burov AA, Podurovskaya YL, Zorov DB, Plotnikov EY, and Sukhikh GT
- Subjects
- Humans, Infant, Child, Rats, Animals, Prospective Studies, Anti-Bacterial Agents therapeutic use, Biomarkers, Neonatal Sepsis complications, Neonatal Sepsis drug therapy, Acute Kidney Injury drug therapy, Acute Kidney Injury etiology, Sepsis complications, Sepsis drug therapy
- Abstract
Aim: Neonatal sepsis remains one of the most dangerous conditions in the neonatal intensive care units. One of the organs affected by sepsis is the kidney, making acute kidney injury (AKI) a common complication of sepsis. Treatment of sepsis almost always involves antibiotic therapy, which by itself may cause some adverse effects, including nephrotoxicity. We analyzed the mutual effect of antibiotic therapy and sepsis on AKI in an experimental and clinical study in infants and neonatal rats., Materials and Methods: We evaluated the influence of therapy with different antibiotics on the appearance of AKI markers (blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), clusterin, interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein 1 (MCP-1), calbindin, glutation-S-transferase subtype π (GST-π)) and liver injury markers in newborns with or without clinical signs of sepsis in the intensive care unit. In parallel, we analyzed the development of AKI in experimental lipopolysaccharide (LPS)-induced systemic inflammation in newborn rats accompanied by antibiotic therapy., Key Findings: We showed that therapy with metronidazole or ampicillin in combination with sulbactam had a beneficial effect in children with suspected sepsis, resulting in a decrease in AKI markers levels. However, treatment of newborns with netilmicin, cefepime, linezolid, or imipenem in combination with cilastatin worsened kidney function in these patients., Significance: This prospective study indicates which antibiotics are preferable in neonatal sepsis and which should be used with caution in view of the risk of AKI development., Competing Interests: Declaration of competing interest The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Intrapartum azithromycin to prevent maternal and neonatal sepsis and deaths: A systematic review with meta-analysis.
- Author
-
Kuitunen I, Kekki M, and Renko M
- Subjects
- Female, Humans, Infant, Newborn, Pregnancy, Chorioamnionitis epidemiology, Chorioamnionitis prevention & control, Randomized Controlled Trials as Topic, Azithromycin administration & dosage, Neonatal Sepsis drug therapy, Neonatal Sepsis mortality, Neonatal Sepsis prevention & control, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious prevention & control, Sepsis drug therapy, Sepsis mortality, Sepsis prevention & control, Peripartum Period
- Abstract
Objectives: A systematic review with met-analysis was performed to summarise the evidence on the effect of intrapartum azithromycin on maternal and neonatal infections and deaths., Search Strategy: PubMed, Scopus and Web of Science databases were searched in March 2023., Selection Criteria: Randomised controlled trials comparing intrapartum single-dose of azithromycin with placebo., Data Collection and Analysis: Maternal infections, maternal mortality, neonatal sepsis, neonatal mortality. We used the random-effects Mantel-Haenszel method to calculate risk ratios (RR) with 95% confidence intervals (95% CI). We assessed risk of bias of the included studies and estimated the evidence certainty using the GRADE approach., Main Results: After screening 410 abstracts, five studies with 44 190 women and 44 565 neonates were included. The risk of bias was low in four and had some concerns in one of the studies. The risk of endometritis was 1.5% in the azithromycin group and 2.3% in the placebo group (RR 0.64, 95% CI 0.55-0.75), and the evidence certainty was high. The respective risk for chorioamnionitis was 0.05% and 0.1% (RR 0.50, 95% CI 0.22-1.18; evidence certainty moderate). The wound infection rate was lower in the azithromycin group (1.6%) than in the placebo group (2.5%), RR 0.52 (95% CI 0.30-0.89; moderate certainty evidence). The maternal sepsis rate was 1.1% in the azithromycin group and 1.7% in the placebo group (RR 0.66, 95% CI 0.56-0.77; evidence certainty high). Mortality rates did not show evidence of a difference (0.09% versus 0.08%; RR 1.26, 95% CI 0.65-2.42; moderate certainty evidence). The neonatal mortality rate was 0.7% in the azithromycin group and 0.8% in the placebo group (RR 0.94, 95% CI 0.76-1.16; moderate certainty evidence). The neonatal sepsis rate was 7.6% in the azithromycin group and 7.4% in the placebo group (RR 1.02, 95% CI 0.96-1.09; moderate certainty evidence)., Conclusions: Intrapartum administration of azithromycin to the mother reduces maternal postpartum infections, including sepsis. Impact on maternal mortality remains undecided. Azithromycin does not reduce neonatal sepsis or mortality rates., (© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
43. Factors associated with neonatal hyperinsulinemic hypoglycemia, a case-control study.
- Author
-
Rattanasakol T and Kitsommart R
- Subjects
- Infant, Infant, Newborn, Female, Pregnancy, Humans, Diazoxide therapeutic use, Case-Control Studies, Fetal Growth Retardation, Glucose therapeutic use, Neonatal Sepsis chemically induced, Neonatal Sepsis complications, Neonatal Sepsis drug therapy, Hypoglycemia complications, Hyperinsulinism complications, Hyperinsulinism drug therapy, Hyperinsulinism epidemiology
- Abstract
Objectives: We aimed to identify perinatal risk factors associated with hyperinsulinemic hypoglycemia in neonates. Secondary objectives included an examination of clinical and biochemical characteristics at the time of diagnosis and an exploration of the duration of diazoxide therapy., Methods: A case-control study was conducted, involving individual chart reviews of inborn infants diagnosed with hyperinsulinemic hypoglycemia (the HH group) between 2014 and 2021. These cases were paired with controls (the non-HH group) belonging to the same gestational age (GA) strata who did not exhibit HH or only had transient postnatal hypoglycemia., Results: A total of 52 infants with HH were matched with corresponding controls. The mean GA in the HH group was 34.4 ± 3.1 weeks. Notably, the HH group exhibited lower mean minimum plasma glucose (PG) levels and required higher glucose infusion rates in comparison to the non-HH group (26.5 ± 15.6 vs. 49.1 ± 37.7 mg/dL and 12.9 ± 3.8 vs. 5.7 ± 2.1 mg/kg/min, respectively; p<0.001 for both). After adjusting for potential confounding factors, only two variables, fetal growth restriction (FGR) and neonatal sepsis, demonstrated significant associations with HH (adjusted odds ratio [95 % confidence interval]: 8.1 [2.1-31.0], p=0.002 and 6.3 [1.9-21.4], p=0.003, respectively). The median duration of diazoxide therapy for the HH group was 4 months., Conclusions: FGR and neonatal sepsis emerged as notable risk factors for HH. These infants exhibited lower PG levels and necessitated higher glucose infusion rates compared to their non-HH counterparts. Importantly, a substantial proportion of the HH group received diazoxide therapy, with a median treatment duration of 4 months., (© 2024 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2024
- Full Text
- View/download PDF
44. Micromotor-based dual aptassay for early cost-effective diagnosis of neonatal sepsis.
- Author
-
Gordón Pidal JM, Arruza L, Moreno-Guzmán M, López MÁ, and Escarpa A
- Subjects
- Infant, Newborn, Humans, Infant, Calcitonin, C-Reactive Protein analysis, Interleukin-6, Reproducibility of Results, Cost-Benefit Analysis, Biomarkers, Procalcitonin, Anti-Bacterial Agents therapeutic use, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Sepsis diagnosis
- Abstract
Given the long-life expectancy of the newborn, research aimed at improving sepsis diagnosis and management in this population has been recognized as cost-effective, which at early stages continues to be a tremendous challenge. Despite there is not an ideal-specific biomarker, the simultaneous detection of biomarkers with different behavior during an infection such as procalcitonin (PCT) as high specificity biomarker with one of the earliest biomarkers in sepsis as interleukin-6 (IL-6) increases diagnostic performance. This is not only due to their high positive predictive value but also, since it can also help the clinician to rule out infection and thus avoid the use of antibiotics, due to their high negative predictive value. To this end, we explore a cutting-edge micromotor (MM)-based OFF-ON dual aptassay for simultaneous determination of both biomarkers in 15 min using just 2 μL of sample from low-birth-weight neonates with gestational age less than 32 weeks and birthweight below 1000 g with clinical suspicion of late-onset sepsis. The approach reached the high sensitivities demanded in the clinical scenario (LOD
PCT = 0.003 ng/mL, LODIL6 = 0.15 pg/mL) with excellent correlation performance (r > 0.9990, p < 0.05) of the MM-based approach with the Hospital method for both biomarkers during the analysis of diagnosed samples and reliability (Er < 6% for PCT, and Er < 4% for IL-6). The proposed approach also encompasses distinctive technical attributes in a clinical scenario since its minimal sample volume requirements and expeditious results compatible with few easy-to-obtain drops of heel stick blood samples from newborns admitted to the neonatal intensive care unit. This would enable the monitoring of both sepsis biomarkers within the initial hours after the manifestation of symptoms in high-risk neonates as a valuable tool in facilitating prompt and well-informed decisions about the initiation of antibiotic therapy.These results revealed the asset behind micromotor technology for multiplexing analysis in diagnosing neonatal sepsis, opening new avenues in low sample volume-based diagnostics., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
45. Enhanced Category-Based Risk Assessment for Neonatal Early-Onset Sepsis: A Prospective Observational Study.
- Author
-
Lau HYS, Wang X, Wong HTM, Lam KHC, and Lam HS
- Subjects
- Humans, Infant, Infant, Newborn, Anti-Bacterial Agents therapeutic use, Prospective Studies, Risk Assessment methods, Risk Factors, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Sepsis diagnosis
- Abstract
Introduction: Compared with multivariate risk assessment, traditional category-based risk assessment (CRA) approaches for neonatal early-onset sepsis (EOS) screening are usually straightforward to use, do not require electronic devices, but are associated with higher rates of antibiotic use. This study aims to evaluate the performance of a novel enhanced CRA (eCRA) framework on EOS admissions and antibiotic use and to investigate whether a modified version with adjustments in risk factor weighting can allow its performance to match the EOS calculator while remaining easy to implement., Method: This is a prospective, single-center, two-phase observational study. Infants of all gestations delivered in a tertiary hospital in Hong Kong with risk factors or clinical features of EOS were recruited., Phase I: A novel eCRA framework (period 2) was compared with the CDC 2010-based protocol (period 1)., Phase Ii: A modified eCRA framework was compared theoretically with the EOS calculator. EOS-specific admissions and antibiotic use were measured., Results: Phase I: 1,025 at-risk infants were recruited during period 2 and compared with 757 infants of period 1. Admissions and antibiotic use decreased from 45.8% to 29.4% and 41.1% to 28.2%, respectively. Antibiotics among those at-risk but well-appearing infants decreased from 25.3% to 16.3% (p < 0.001 for all)., Phase Ii: antibiotic use was similar (7.3 vs. 6.4%, p = 0.42) between the modified eCRA framework and the EOS calculator., Conclusions: An eCRA framework can effectively and safely provide individualized guidance for EOS screening without the need for tools such as the EOS calculator., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
46. Improved efficiency in the management of newborns with infectious risk factors by the sepsis risk calculator and clinical observation.
- Author
-
Mazabanda López DA, Urquia Martí L, Reyes Suárez D, Siguero Onrubia M, Borges Luján M, and García-Muñoz Rodrigo F
- Subjects
- Female, Humans, Infant, Newborn, Cohort Studies, Birth Weight, Anti-Bacterial Agents therapeutic use, Risk Factors, Risk Assessment, Retrospective Studies, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Neonatal Sepsis etiology, Chorioamnionitis drug therapy, Sepsis diagnosis, Sepsis drug therapy
- Abstract
Objective: To evaluate the efficiency of the sepsis risk calculator and the serial clinical observation in the management of late preterm and term newborns with infectious risk factors., Method: Single-center, observational, two-phase cohort study comparing the rates of neonates born ≥35 weeks' gestation, ≥2000 g birthweight, and without major congenital anomalies, who were screened and/or received antibiotics for early-onset neonatal sepsis risk at our center during two periods, before (January/2018-June/2019) and after (July/2019-December/2020) the implementation of the sepsis risk calculator., Results: A total of 1796 (Period 1) and 1867 (Period 2) patients with infectious risk factors were included. During the second period, tests to rule out sepsis were reduced by 34.0 % (RR, 95 %CI): 0.66 (0.61, 0.71), blood cultures by 13.1 %: 0.87 (0.77, 0.98), hospital admissions by 13.5 %: 0.86 (0.76, 0.98) and antibiotic administration by 45.9 %: 0.54 (0.47, 0.63). Three cases of early-onset neonatal sepsis occurred in the first period and two in the second. Clinical serial evaluation would have detected all true cases., Conclusions: The implementation of a sepsis risk calculator in the management of newborns ≥35 weeks GA, ≥2000 g birthweight, without major congenital anomalies, with infectious risk factors is safe and adequate to reduce laboratory tests, blood cultures, hospital admissions, and antibiotics administration. Serial clinical observation, in addition, could be instrumental to achieve or even improve this goal., Competing Interests: Conflicts of interest No financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article., (Copyright © 2023 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Pragmatic Expansion of a Neonatal Antibiotic Stewardship Program in a Community Health Care System.
- Author
-
Martin JS, Botta CJ, Bowman S, and Giliberti D
- Subjects
- Infant, Infant, Newborn, Humans, Anti-Bacterial Agents therapeutic use, Intensive Care Units, Neonatal, Community Health Services, Antimicrobial Stewardship methods, Neonatal Sepsis drug therapy
- Abstract
Background: Previously published neonatal antibiotic stewardship efforts have been primarily implemented in single centers. Piedmont Athens Regional began work to decrease antibiotic use in the NICU with spread to the newborn nursery (NBN) and, subsequently, 13 other NICUs and NBNs throughout a health care system over a 4-year period., Methods: This quality improvement initiative was conducted in the context of a multicenter learning collaborative from 2016 to 2019. The primary aim was a 10% reduction in antibiotic days per 1000 patient days (antibiotic utilization rate [AUR]) among newborns in the NICU and NBN at each hospital by December 2018. Change ideas were implemented by using plan-do-study-act cycles. The primary outcome measure was AUR with a balancing measure of antibiotic restarts., Results: Piedmont Athens Regional decreased the NICU AUR by 46% and NBN AUR by 83%. Piedmont Healthcare decreased the NICU AUR by 40% and NBN AUR by 74%. Seven of 8 NICUs and 5 of 7 NBNs achieved a >10% reduction in AUR and 8 of 8 intervention hospitals showed a sustained drop in AUR in the NBN, NICU, or both during the 1.5-year postobservation period. Decreases in antibiotic initiation resulted in 335 fewer antibiotic courses in the NICU and 189 fewer infants started on antibiotics in the NBN in 2020 versus 2017., Conclusions: This initiative achieved reductions in AUR across multiple hospitals in the network. The system-wide approach facilitated information technology (IT) and electronic health record modifications. Common drivers of NICU improvement were involvement for at least 2 years, multidisciplinary teams, and the highest baseline AUR. The common driver of nursery improvement was the implementation of a neonatal sepsis risk calculator., (Copyright © 2024 by the American Academy of Pediatrics.)
- Published
- 2024
- Full Text
- View/download PDF
48. Short course of intravenous antibiotics in the treatment of uncomplicated proven neonatal bacterial sepsis: A systematic review.
- Author
-
Aljarbou A, Cuello C, and Leslie ATFS
- Subjects
- Infant, Infant, Newborn, Humans, Anti-Bacterial Agents therapeutic use, Hospitalization, Treatment Failure, Neonatal Sepsis drug therapy, Sepsis drug therapy
- Abstract
Aim: To evaluate the efficacy and harms of a short (7-10 days) compared with a standard (10-14 days) duration of antibiotics in culture-proven neonatal sepsis for reducing all-cause mortality, treatment failure and duration of hospitalisation., Methods: Medline, EMBASE and Cochrane CENTRAL were searched for randomised trials., Results: We included five studies, all conducted in India (447 infants with a gestational age greater than 32 weeks). Except for one study, all studies were at high risk of bias. All-cause mortality was reported in three studies with only one death reported in the standard duration regimen arm (243 patients, very low certainty). A meta-analysis showed no evidence of the effect on treatment failure (RR of 1.47 [95% CI 0.48-4.50], 440 patients, five studies, very low certainty) of short-term antibiotics. Short-term antibiotic regimen shortened the duration of hospitalisation by 4 days (mean difference of -4.04 days [95% CI -5.47 to -2.61]; 4 studies; 371 patients; very low certainty)., Conclusion: Among studies focused on infants born with a gestational age greater than 32 weeks, short-term administration of antibiotics may shorten the duration of hospitalisation, but the evidence is very uncertain. The evidence on other predefined outcomes is very uncertain to draw definite conclusions., (© 2023 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
49. Neonatal early-onset sepsis calculator: Impact on antibiotic use in a level II neonatal unit in Western Australia.
- Author
-
Gannon J, Strunk T, Friesen N, and Saw C
- Subjects
- Infant, Newborn, Infant, Pregnancy, Female, Humans, Anti-Bacterial Agents therapeutic use, Western Australia, Retrospective Studies, Risk Assessment, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Sepsis drug therapy, Sepsis epidemiology
- Abstract
Background: Overuse of empirical intravenous antibiotics in neonates in high-income countries (HICs) is well documented. The Kaiser Permanente neonatal early-onset sepsis (EOS) calculator is an evidence-based sepsis risk assessment tool that has demonstrated potential to reduce antibiotic usage in this population. The incidence of early-onset sepsis in most HICs is 0.4-0.8 per 1000 live births. The objective was to evaluate the calculator's impact on antibiotic rates and length of stay in a regional level II Special Care Nursery., Methods: A single-centre retrospective cohort study compared antibiotic administration rates in the first 72 h in neonates ≥35 weeks gestation born during two 6-month periods in 2019 (pre-EOS calculator) and 2021 (post-EOS calculator). Electronic and paper case records were accessed to capture data. Continuous data were summarised using mean and standard deviation, and categorical data were summarized using frequency distributions. There were 951 (2019) and 1129 (2021) infants born during the study periods., Results: Following implementation of the calculator, antibiotic exposure decreased from 13.7% to 4.7% of all neonates without reported negative outcomes. Mean length of stay for neonates born across the two periods decreased from 2.38 to 2.13 days. Indications for antibiotic use shifted more towards clinical condition and away from obstetric risk factors. There were no culture-proven cases of sepsis or readmissions with EOS in either period., Conclusion: Implementation of the EOS calculator significantly reduced exposure to antibiotics, without adverse outcomes., Competing Interests: Declaration of competing interest The authors have no conflicts of interest relevant to this article and no funding was received for conducting this study., (Copyright © 2023 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Game changer or gimmick: inflammatory markers to guide antibiotic treatment decisions in neonatal early-onset sepsis.
- Author
-
Stocker M and Giannoni E
- Subjects
- Infant, Newborn, Humans, Anti-Bacterial Agents therapeutic use, Biomarkers, C-Reactive Protein analysis, Neonatal Sepsis diagnosis, Neonatal Sepsis drug therapy, Sepsis diagnosis, Sepsis drug therapy
- Abstract
Background: The diagnosis of neonatal early-onset sepsis (EOS) is challenging, and inflammatory markers are widely used to guide decision-making and therapies., Objectives: This narrative review presents the current state of knowledge regarding the diagnostic value and potential pitfalls in the interpretation of inflammatory markers for EOS., Sources: PubMed until October 2022 and searched references in identified articles using the search terms: neonatal EOS, biomarker or inflammatory marker, and antibiotic therapy or antibiotic stewardship., Content: In situations with a high or low probability of sepsis, the measurements of inflammatory markers have no impact on the decision to start or stop antibiotics and are just gimmick, whereas they may be a game changer for neonates with intermediate risk and therefore an unclear situation. There is no single or combination of inflammatory markers that can predict EOS with high probability, allowing us to make decisions regarding the start of antibiotics based only on inflammatory markers. The main reason for the limited accuracy is most probably the numerous noninfectious conditions that influence the levels of inflammatory markers. However, there is evidence that C-reactive protein and procalcitonin have good negative predictive accuracy to rule out sepsis within 24 to 48 hours. Nevertheless, several publications have reported more investigations and prolonged antibiotic treatments with the use of inflammatory markers. Given the limitations of current strategies, using an algorithm with only moderate diagnostic accuracy may have a positive impact, as reported for the EOS calculator and the NeoPInS algorithm., Implications: As the decision regarding the start of antibiotic therapy is different from the process of stopping antibiotics, the accuracy of inflammatory markers needs to be evaluated separately. Novel machine learning-based algorithms are required to improve accuracy in the diagnosis of EOS. In the future, inflammatory markers included in algorithms may be a game changer reducing bias and noise in the decision-making process., Competing Interests: Transparency declaration The authors declare that they have no conflicts of interest., (Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.